Welcome to "Fly Insider," The Fly's weekly recap of notable insider stock transactions.

NOTABLE INSIDER PURCHASES: Significant insider purchases reported in the prior week from November 23 through November 27 include:

• Beneficial owner of BioLife Solutions (BLFS) Casdin Partners purchased 1,600,000 shares of company stock at $22.50 per share for a total transaction value of $36,000,000

• Director of Net 1 UEPS Technologies (UEPS) Anthony Ball purchased 88,911 shares of company stock at $3.39 per share for a total transaction value of $301,408

• Director of Merrimack Pharmaceuticals (MACK) Eric Andersen purchased 69,088 shares of company stock at $3.65 per share for a total transaction value of $252,171

• Beneficial owner of FTS International (FTSI) THRC Holdings purchased 876,280 shares of company stock at $15.33 per share for a total transaction value of $13,435,475

• Director of Coty (COTY) Johannes Huth purchased 1,000,000 shares of company stock at $6.20 per share for a total transaction value of $6,199,000

NOTABLE INSIDER SALES: Significant insider sales in the prior week from November 23 through November 27 include:

• Director of Catalent (CTLT) Peter Zippelius sold 5,392,280 shares of company stock at $99.26 per share for a total transaction value of $535,237,713

• Beneficial owner of Container Store Group (TCS) Green Equity sold 5,500,000 shares of company stock at $10.00 per share for a total transaction value of $55,000,000

• Chairman of Carlyle Group (CG) David Rubinstein sold 2,000,000 shares of company stock at $27.30 per share for a total transaction value of $54,600,000

• Beneficial owner of Duck Creek Technologies (DCT) Accenture sold 480,000 shares of company stock at $39.77 per share for a total transaction value of $19,089,600

• COO of Palantir Technologies (PLTR) Shyam Sankar sold 600,000 shares of company stock at $20.42 per share for a total transaction value of $12,250,620. 

NOTABLE PRICE MOVEMENT AFTER INSIDER TRANSACTION: Shares of Merrimack Pharmaceuticals are up 13% since Eric Andersen purchased 69,088 shares, while shares of Catalent are down over 6% since director Peter Zippelius sold 5.39M shares.